5 Key Takeaways
-
1
The 2026 American Glaucoma Society Meeting showcased advancements in minimally invasive glaucoma surgery (MIGS) technologies.
-
2
Investigational devices include sustained-release drug delivery systems, laser-based procedures, and new stents targeting aqueous outflow.
-
3
Dr. Rachel Simpson emphasized the importance of addressing regulatory and reimbursement challenges for successful clinical adoption of MIGS.
-
4
Innovative devices like the eyeFlow microstent and Intercil Uveal Spacer represent new approaches to enhancing aqueous outflow.
-
5
Engagement with the FDA and advocacy for supportive regulatory frameworks are crucial for integrating new MIGS technologies into practice.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.